对HIV被动施用 “广谱中和抗体” (bNAbs)在HIV-1感染的人化小鼠和猕猴模型中对防止HIV-1感染一直都是有效的。曾有人提出，bNAbs(被动施用或通过病毒载体来施用)对于人类的预防和免疫治疗来说可能也是有效的。该方法的安全性和疗效以前没有在人体上进行过试验，但在这篇论文中，Michel Nussenzweig及同事报告了将中和抗体指向CD4结合点的一项I-期被动免疫研究的结果，发现这种治疗方法可以瞬时降低人体的HIV病毒载量。

 

    原文链接：Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

 

    原文摘要：HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was therefore abandoned. However, recently developed single-cell-based antibody cloning methods have uncovered a new generation of far more potent broadly neutralizing antibodies to HIV-1 . These antibodies can prevent infection and suppress viraemia in humanized mice and nonhuman primates, but their potential for human HIV-1 immunotherapy has not been evaluated. Here we report the results of a first-in-man dose escalation phase 1 clinical trial of 3BNC117, a potent human CD4 binding site antibody, in uninfected and HIV-1-infected individuals. 3BNC117 infusion was well tolerated and demonstrated favourable pharmacokinetics. A single 30 mg kg?1 infusion of 3BNC117 reduced the viral load in HIV-1-infected individuals by 0.8–2.5 log10 and viraemia remained significantly reduced for 28 days. Emergence of resistant viral strains was variable, with some individuals remaining sensitive to 3BNC117 for a period of 28 days. We conclude that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure.